Document Detail

Computational modeling and epidemiologic approaches: a new section of the Journal of Translational Medicine.
Jump to Full Text
MedLine Citation:
PMID:  23075423     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A new section of the Journal of Translational Medicine is being introduced to encourage rapid communication of methods and results that utilize computational modeling and epidemiologic approaches in translational medicine. The focus will be on population-based studies that extend towards more molecular level analysis. Submission of studies involving methods development is encouraged where actual application and results can be shown in the healthcare and life sciences domains.
Authors:
Michael N Liebman; Sabrina Molinaro
Related Documents :
11775503 - A framework for assessing the impact of the ippc directive on the performance of the pi...
17285183 - Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and applic...
21810043 - The composition and origin of ghana medicine clays.
Publication Detail:
Type:  Editorial     Date:  2012-10-17
Journal Detail:
Title:  Journal of translational medicine     Volume:  10     ISSN:  1479-5876     ISO Abbreviation:  J Transl Med     Publication Date:  2012  
Date Detail:
Created Date:  2012-11-12     Completed Date:  2013-04-01     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  101190741     Medline TA:  J Transl Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  210     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Computational Biology*
Epidemiologic Studies*
Translational Medical Research*
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Transl Med
Journal ID (iso-abbrev): J Transl Med
ISSN: 1479-5876
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2012 Liebman and Molinaro; licensee BioMed Central Ltd.
open-access:
Received Day: 16 Month: 10 Year: 2012
Accepted Day: 16 Month: 10 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 17 Month: 10 Year: 2012
Volume: 10First Page: 210 Last Page: 210
PubMed Id: 23075423
ID: 3494520
Publisher Id: 1479-5876-10-210
DOI: 10.1186/1479-5876-10-210

Computational modeling and epidemiologic approaches: a new section of the journal of translational medicine
Michael N Liebman1 Email: m.liebman@strategicmedicine.com
Sabrina Molinaro2 Email: sabrina.molinaro@ifc.cnr.it
1Strategic Medicine, Inc, 231 Deepdale Drive, Kennett Square, PA 19348, USA
2Institute of Clinical Physiology, National Research Council, Pisa, Italy

Editorial

We introduce a new section of the Journal of Translational Medicine to encourage rapid communication of methods and results that utilize computational modeling and epidemiologic approaches in translational medicine. The focus will be on population-based studies that extend towards more molecular level analysis. Submission of studies involving methods development is encouraged where actual application and results can be shown in the healthcare and life sciences domains.

We acknowledge the “flood of data” emanating from new technologies, e.g. genomic sequencing, but we must also consider the enormity of data already existing in clinical histories and observational studies, nationally and internationally. There remains a critical need to re-focus translational medicine on the clinical perspective, starting with clinical need, to enhance the value of molecular-based approaches. Both perspectives fundamentally drive clinical utility and are very complementary and have been discussed in editorials in this journal [1,2].

Ultimately translational medicine must improve patient care and enhance patient-physician communication and decision-making. Patients are complex biological systems (processes) that evolve over time under the influence of many factors, e.g. environmental, lifestyle, etc. that cause an individual’s genomic risk to progress to disease. It is critical to understand, represent, analyze and interpret patients and disease, temporally, to acknowledge the complexity of disease presentation, diagnosis and treatment that go beyond genomic make-up. The successful integration of a more clinical/epidemiological base and one using high throughput technology to develop high resolution, but static, representation of a patient’s state is critical in personalized and stratified medicine.

Genomic sequencing and gene expression analysis appear yield “quantitative” data for the bioinformatics community with little experience addressing clinical or epidemiologic data. These last two are viewed as “softer” or more “qualitative” but the reality of translational medicine can only succeed these data sources approach a continuum rather than separable silos. Accurate diagnosis of a patient is required to address stratification, disease sub-typing, reliability of diagnostic criteria, physician compliance with guidelines and different EHR’s and can limit the correlation of molecular observation with clinical manifestation. Extending this correlation towards critical mechanistic understanding would become impossible. Medical informatics has focused on immediate patient management and does not necessarily address the comprehensive data collection and data models necessary to support molecular studies and analysis.

Approaches to be highlighted in this section include:

1. Data-mining for health impact: The availability of large data resources, e.g. EHR’s, PHR’s, HIE’s, registries, observational studies, etc. provide the opportunity to identify and extract patterns of patient histories, pre-disease, at time of diagnosis, response to treatment and treatment outcome that can contribute to preventive and predictive medicine and improved patient management. The development of high quality data resources and the advancement of methodologies to enable this data-mining are important aspects in making these activities translational. Additional development of appropriate ontologies to represent the complex knowledge necessary for translational research is also critical [3].

2. Data modeling: Data-modeling is both a passive and an active process. Conventional data modeling creates models to link disparate data, with a functional theme, e.g. disease progression: pre-disease to outcome. Expanding this view, to include a semantic data model, involves identifying missing data elements critical to complete a functional data model and supports the additional collection of such data [4].

3. Health record system design: The success of predictive approaches requires availability of electronic documents generated when patient and the health care infrastructure interact, including: hospital stays, surgery records, drug prescriptions, specialist health-care, death registries and EHR’s. Data flows trace the pathological history of a patient over time, and emphasize the evolution of diseases [5].

4. Applications of epidemiologic analysis: The patterns, causes, and effects of health and disease conditions in defined populations form the cornerstone of public health, and impacts policy decisions and evidence-based medicine by identifying risk factors for disease and targets for preventive medicine [6].

5. Public policy evaluation: A critical aspect of translational research is to reflect the impact of public policy as well as to potentially effect its development and implementation [7].

6. Hypothesis evaluation and testing: Robust and comprehensive analysis of the fundamental hypothesis of a study can identify early risks and opportunities and optimize study design in both clinical and observational studies [8].

7. Risk assessment in healthcare and life sciences: How early can risk be detected? How can we identify, prioritize and quantify the dimensions of risk (and opportunity?) [9].

8. Measuring and correcting for effects of missing or conflicting data: Methods to detect and potentially correct, possibly through modeling/simulation, missing or conflicting data are critical to optimize data analysis and interpretation [10].

9. Stratifying disease versus stratifying patients: Clinical observations and patient history can provide temporal portraits of disease that complement genomic identification of risk and lead to improved patient management [11].

10. Qualifying Data Content and quality: Important data sources exist containing lifestyle and socio cultural environment data, e.g. eating habits, socio-economic situation, legal substance (tobacco, alcohol and psychoactive drugs) use and illegal substance use. These data sources include surveys. Other important data may be Air Pollution Data Sources, i.e. air quality data [12].

Submitted articles should describe how the approach and results reflect the computational modeling and epidemiologic aspects of translational medicine derived both from the richness of the data available (or to be developed), and from the versatility of analysis methodologies, to contextually answer to the needs in:

prevention (identification and evaluation of modifiable risk factors)

diagnosis (optimization of early detection, stratification and staging)

therapy (stratification of disease and personalization of treatment)

health offer planning (optimization of service offerings based on volumes and health profiles of the population)

compliance (to clinical practice guidelines, to patient behavior, to following physician orders)

personalization (disease stratification based on clinical presentation)

patient management (integration of patient stratification, e.g. genomics, disease stratification and therapeutic options/outcomes)

forecasts (predictive models for patient subgroups for use in prevention, behavior modification, cost estimation, etc.)

public policy (relationship between policies and public/patient/physician response; evidence for opportunities to impact policy development)


Competing interests

No competing interests exist.


References
Marincola FM,Translational Medicine: a two-way roadJ Transl MedYear: 200311 24 July 2003. 10.1186/1479-5876-1-114527344
Liebman MN,Marincola FM,Expanding the perspective of translational medicine: the value of observational dataJ Transl MedYear: 2012106110.1186/1479-5876-10-6122452969
Hian Chye K,Tan G,Data Mining Applications in HealthcareJ Healthc Inf ManagYear: 2005192
Shahid S,How to design next-generation EHR data models, Healthcare IT NewsYear: 2012 ,  
Electronic Health Record StandardsHealth Policy Brief, Health AffairsYear: 2010RW Johnson Foundation, Georgetown, MD
Siciliano V,Pitino A,Gori M,Curzio O,Fortunato L,Liebman M,Molinaro S,The Application of Observational Data in Translational Medicine: Analyzing Tobacco-Use Behaviors of AdolescentsJ Transl MedYear: 20121089 14 May 2012. 10.1186/1479-5876-10-8922583654
Cole BL,Fielding JE,Health Impact Assessment: A Tool to Help Policy Makers Understand Health Beyond Health CareAnnu Rev Public HealthYear: 20072839341210.1146/annurev.publhealth.28.083006.13194217173539
Liebman MN,Molinaro S,Hypothesis Generation and Evaluation in Clinical Trial DesignBIBMYear: 2011645651 Proceedings of BIBM 2011.
Nelson HD,Huffman LH,Fu R,Harris EL,U.S. Preventive Services Task Force, Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task ForceAnn Intern MedYear: 2005143536237916144895
Nich C,Carroll KM,‘Intention-to-treat’ meets ‘missingdata’: implications of alternate strategies for analyzing clinical trials dataDrug Alcohol DependYear: 200268212113010.1016/S0376-8716(02)00111-412234641
Verma M,Seminara D,Fernando AJ,Christy J,Iwamoto K,Hartmuller V,Genetic and Epigenetic Biomarkers in Cancer: Improving Diagnosis, Risk Assessment, and Disease StratificationMol Diagn TherYear: 200610111510.1007/BF0325643816646573
Hu H,Correll M,Kvecher L,Osmond M,Clark J,Bekhash A,Schwab G,Gao D,Gao J,Kubatin V,Shriver CD,Hooke JA,Maxwell LG,Kovatich AJ,Sheldon JG,Liebman MN,Mural RJ,DW4TR: A Data Warehouse for Translational ResearchJ Biomed InformYear: 2011441004101910.1016/j.jbi.2011.08.00321872681

Article Categories:
  • Editorial


Previous Document:  Prognostic impact of FOXP3 expression in triple-negative breast cancer.
Next Document:  Expression of LY6D is induced at the surface of MCF10A cells by X-ray irradiation.